IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis

International Journal of Rheumatic Diseases

Volumn 17, Issue 8, 2014, Pages 872-877

  Sakthiswary, Rajalingham ^a   Shaharir, Syahrul S ^a   Mohd Said, Mohd S ^a   Asrul, Abdul W ^a   Shahril, Nor S ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b PUTRAJAYA HOSPITAL   (Malaysia)

Author keywords

IgA rheumatoid factor; Rheumatoid arthritis; Rheumatoid factor isotypes; Tumour necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; CYCLOPEPTIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922482349     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12443     Document Type: Article

References (22)

1. Hyrich KL, Watson KD, Silman AJ, Symmons DP (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45 (12), 1558-65.
2. Teitsson I, Valdimarsson H (1984) Use of monoclonal antibodies and F(ab')2 enzyme conjugates in ELISA for IgM, IgA and IgG rheumatoid factors. J Immunol Methods 71, 149-61.
3. Bobbio-Pallavicini F, Caporali R, Alpini C et al. (2007) High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 66, 302-7.
4. Alessandri C, Bombardieri M, Papa N et al. (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63 (10), 1218-21.
5. Mikuls TR, O'Dell JR, Stoner JA et al. (2004) Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 50 (12), 3776-82.
6. De Rycke L, Verhelst X, Kruithof E et al. (2005) Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64 (2), 299-302.
7. Atzeni F, Sarzi-Puttini P, Dell'Acqua D et al. (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8 (1), R3.
8. Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A et al. (2005) Blockade of tumour necrosis factor alpha significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 64 (8), 1224-6.
9. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6, R264-72.
10. Taneja V, Mehra NK, Kailash S, Anand C, Malaviya AN (1992) Protective & risk DR phenotypes in Asian Indian patients with rheumatoid arthritis. Indian J Med Res 96, 16-23.
11. Barton A, Bowes J, Eyre S et al. (2004) A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum 50 (4), 1117-21.
12. Aletaha D, Neogi T, Silman AJ et al. (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (9), 1580-8.
13. Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23 (Suppl. 39), S93-9.
14. Thompson PW, Pegley FS (1191) A comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients. Br J Rheumatol 30(4), 298-300.
15. Lequerre T, Jouen F, Brazier M et al. (2007) Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) 46 (3), 446-53.
16. Smolen JS, Landewe R, Breedveld FC et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73 (3), 492-509.
17. Teitsson I (1988) IgA rheumatoid factor as predictor of disease activity. Scand J Rheumatol Suppl 75, 233-7.
18. Bas S, Perneger TV, Kunzle E, Vischer TL (2002) Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann Rheum Dis 61, 505-10.
19. Swedler W, Wallman J, Froelich CJ, Teodorescu M (1997) Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. J Rheumatol 24 (6), 1037-44.
20. Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42 (5), 677-80.
21. Berglin E, Johansson T, Sundin U et al. (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 65 (4), 453-8.
22. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47 (4), 495-9.